1-6 of 6
Abualbishr Alshreef
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab, Gemcitabine, and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Javier Munoz, Allison C. Rosenthal, Andrew Ip, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7760.
https://doi.org/10.1182/blood-2024-203876
Published: 2024
Journal Articles

Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients: A Match-Adjusted Comparative Analysis

Andrew Ip, Javier Munoz, Allison C. Rosenthal, Justin M. Darrah, Tongsheng Wang, Guihua Zhang, Alex Mutebi, Monika Jun, Zhijie Ding, Anindit Chhibber, Fernando Rivas Navarro, Malene Risum, Mohammad Atiya, Samantha Brodkin, Anthony W Wang, Abualbishr Alshreef, Diala Harb, Mariana Sacchi, Daniela Hoehn, Yasmin H. Karimi
Journal: Blood
Blood (2024) 144 (Supplement 1): 7757.
https://doi.org/10.1182/blood-2024-203540
Published: 2024
Journal Articles

Cost-Effectiveness of Epcoritamab Versus Glofitamab in Relapsed or Refractory Large B-Cell Lymphoma after at Least Two Lines of Therapy in the United States

Christopher P Fox, Peter A. Riedell, Tingting Qu, Monika Jun, Anindit Chhibber, Alex Mutebi, Huimin Li, Yang Meng, Anthony W Wang, Abualbishr Alshreef
Journal: Blood
Blood (2024) 144 (Supplement 1): 7614.
https://doi.org/10.1182/blood-2024-207898
Published: 2024
Journal Articles

Indirect Comparisons of the Efficacy of Epcoritamab Vs Glofitamab in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

John N. Allan, Christopher P Fox, Grzegorz S. Nowakowski, Peter A Riedell, Tycel J. Phillips, Anthony W Wang, Abualbishr Alshreef, Junhua Yu, Cheng Chen, Kavita Sail, Diala Harb, Alex Mutebi, Anindit Chhibber, Brian Elliot, Mohammad Atiya, Catherine Thieblemont
Journal: Blood
Blood (2024) 144 (Supplement 1): 2349.
https://doi.org/10.1182/blood-2024-203994
Published: 2024
Journal Articles

Efficacy of Subcutaneous Epcoritamab Vs Tisa-Cel in R/R LBCL CAR T-Naive and CAR T-Eligible Patients: An Indirect Comparison

Gilles Salles, Christopher P. Fox, Anthony Wang, Kavita Sail, Abualbishr Alshreef, Michael Moran, Alex Mutebi, Julie Blaedel, Viktor Chirikov, Wei-Jhih Wang, Catherine Thieblemont
Journal: Blood
Blood (2023) 142 (Supplement 1): 1733.
https://doi.org/10.1182/blood-2023-180047
Published: 2023
Journal Articles

Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Gilles Salles, Anthony Wang, Alex Mutebi, Abualbishr Alshreef, Kalatu R. Davies, Gijs van de Wetering, Viktor Chirikov
Journal: Blood
Blood (2022) 140 (Supplement 1): 10934–10935.
https://doi.org/10.1182/blood-2022-158028
Published: 2022